Shortage of recently approved Beyfortus™ (nirsevimab-alip) due to high demand
October 25, 2023 - Currently, there is a nationwide shortage of Sanofi's Beyfortus (nirsevimab-alip), a monoclonal antibody used in newborns and infants to protect against respiratory syncytial virus (RSV) disease due to increased demand.
Top